The study suggests that pretreatment cytokine profiling, particularly focusing on IL-6 and IL-2R, could effectively identify high-risk cHL patients prone to early-disease relapse and may serve as an additional prognostic tool beyond existing risk stratification methods [91]. This evidence concerns the gene IL2RA and classic Hodgkin lymphoma.